UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K/A

Current Report

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 1, 2015

CORTEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware	1-16467	33-0303583
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S Employer Identification No.)

126 Valley Road, Suite C Glen Rock, New Jersey	07452
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (201) 444-4947

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Explanatory Note

On May 1, 2015, Cortex Pharmaceuticals, Inc. (the "Company") filed a Current Report on Form 8-K (the "Original Report") that furnished, as Exhibit 99.1, a collection of slides that the Company intended to use at its presentation at the New York BIO 25th Anniversary Conference (the "Conference") on May 4, 2015. The Company made its presentation at the Conference as scheduled.

Among other things, those slides referred to a clinical study of the compound dronabinol, which was being conducted by the University of Illinois. Based on disclosures by the University of Illinois, the Company expected the clinical study to be completed in the third quarter of 2015. After the Conference, the University of Illinois disclosed that the expected completion date for the clinical study had been changed to May 2016. Accordingly, attached as Exhibit 99.1 to this Current Report on Form 8-K/A are revised slides (the "Revised Slides") from the original exhibit that referenced the clinical study, updated to reflect the new anticipated completion date of the clinical study. The full slide deck, with the Revised Slides, will also be available on the Company's web-site.

The remainder of the information provided with the Original Report remains unchanged.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

A list of exhibits that are furnished as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 18, 2015

CORTEX PHARMACEUTICALS, INC.
(Registrant)

By: */s/ ARNOLD S. LIPPA*
Arnold S. Lippa
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Exhibit Description
99.1	Revised Slides amending certain slides furnished as Exhibit 99.1 to the Company's Current Report on Form 8-K filed May 1, 2015*

*Furnished herewith.

Exhibit 99.1


CORTEX
PHARMACEUTICALS, INC.
Cortex Pharmaceuticals, Inc.
May 15, 2015

Background

2013

- Insolvent & near bankruptcy
- No ongoing operations
- Lost dronabinol license
- Deficient in SEC reporting
- Approx. $3M market cap

Today

- Non-bankruptcy reorganization
- New capital raised
- Re-gained dronabinol license
- Current in SEC reporting
- Approx. $25M market cap
- Newly organized research program
- Phase 2B dronabinol clinical trial to be completed May 2016
- Phase 2A ampakine clinical trial to begin 3Q, pending financing
- Committed management team and board of directors

Dronabinol for Treatment of OSA: A Phase 2 Compound

- **Mechanism of Action**
  - Dronabinol is (Δ-9)THC, a cannabinoid agonist
- **Commercial Status**
  - FDA approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy
  - Schedule III drug available by prescription, low risk of addiction
- **Stage of Development**
  - Phase 2A data demonstrates statistically significant improvement in OSA
  - Phase 2B study in OSA is in progress with completion in May 2016
- **Intellectual Property**
  - Issued method-of-use patent in the US for the use of Dronabinol for treating OSA (expires 2025) & pending patents on modified release formulations
- **Funding**
  - NIH funded $5MM grant for Phase 2B study in OSA

Dronabinol Phase 2B Trial in Chronic, Obstructive Sleep Apnea

- Phase 2B study in progress at University of Illinois
- 120 subjects (40/group, 6 wks dosing)
- Doses: Placebo, 2.5 mg, 10 mg qd
- Study costs funded by NIH Grant for $5 MM
- Top line data by May 2016

Key Objectives for the Next 12 Months

Compound	Indication	Status	Estimated Start Date	Estimated Completion
Dronabinol	Obstructive Sleep Apnea	Phase IIB	started	May 2016
CX1739	Opiate-induced RD	Phase IIA	2Q2015	3Q2015
	Propofol-induced RD	Phase IIA	3Q2015	4Q2015
CX1739/CX717	Pompe Disease	Phase IIA	4Q2015	2Q2016
CX1942	Injectable for RD	Pre-clinical studies	3Q2014	2Q2015